100 November Sustainable Dividend Dogs: 50 'Safer' And 2 Ideal Buys
Calvert Research and Management ranked the 100 most sustainable companies based on over 230 ESG indicators. Read here for our picks.
Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
Reuters19h
Merck KGaA Q3 earnings rise faster than expected on lower costs
FRANKFURT, Nov 14 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly ...
Merck in Cancer Licensing Pact With LaNova Medicines
Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
CHMP issues positive recommendation for approval of lecanemab in the EU
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai ...